TTX Stock Overview A clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Theralase Technologies Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Theralase Technologies Historical stock prices Current Share Price CA$0.17 52 Week High CA$0.29 52 Week Low CA$0.074 Beta 1.18 1 Month Change -14.95% 3 Month Change 2.48% 1 Year Change 39.83% 3 Year Change -46.08% 5 Year Change 2.48% Change since IPO -43.69%
Recent News & Updates
Theralase Technologies Inc. Launches Three New Clinical Study Sites in USA Dec 10
Theralase(R) Launches New Clinical Study Site in Canada Dec 06 Theralase Technologies Inc. announced that it has received CAD 0.6664 million in funding Nov 16
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study Oct 07 Theralase Technologies Inc. announced that it has received CAD 0.544 million in funding Sep 25
Theralase Technologies Inc. Demonstrates Unique Ability to Activate Rutherrin with Diabetes Drug Aug 21 See more updates
Theralase Technologies Inc. Launches Three New Clinical Study Sites in USA Dec 10
Theralase(R) Launches New Clinical Study Site in Canada Dec 06 Theralase Technologies Inc. announced that it has received CAD 0.6664 million in funding Nov 16
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study Oct 07 Theralase Technologies Inc. announced that it has received CAD 0.544 million in funding Sep 25
Theralase Technologies Inc. Demonstrates Unique Ability to Activate Rutherrin with Diabetes Drug Aug 21
Second quarter 2024 earnings released: CA$0.005 loss per share (vs CA$0.005 loss in 2Q 2023) Aug 13 Theralase Technologies Inc. announced a financing transaction Jul 09
Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy Jun 21
Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy Jun 14
Theralase Technologies Inc. Announces Ruvidar Enhances Efficacy of Cancer Drug Jun 13
Theralase Technologies Inc. Successfully Destroys Lung Cancer Jun 08
Theralase® Technology Effective in Virus Inactivation Jun 06
First quarter 2024 earnings released: CA$0.006 loss per share (vs CA$0.007 loss in 1Q 2023) Jun 04 Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding Apr 25
Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding Apr 24
Theralase Technologies Inc., Annual General Meeting, Jun 19, 2024 Apr 23
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent Apr 05
Full year 2023 earnings released: CA$0.021 loss per share (vs CA$0.025 loss in FY 2022) Mar 28 Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding Feb 06
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study Jan 15
Forecast to breakeven in 2026 Dec 31
Third quarter 2023 earnings released: CA$0.005 loss per share (vs CA$0.007 loss in 3Q 2022) Nov 30 Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding Nov 30
Theralase Technologies Inc. announced that it expects to receive CAD 1.5 million in funding Nov 18
Theralase® Technologies Inc. Announces That It Has Been Granted Clinical Trial Application Amendment by Health Canada Through Receipt of A No Objection Letter for the Optimization of the Phase Ii Non-Muscle Invasive Bladder Cancer Clinical Study Oct 24
Theralase Technologies Inc. Provides Update on Bladder Cancer Clinical Study Oct 17
Theralase Technologies Inc. Files US Patent for Enhanced Immunotherapy Oct 06
Theralase®? Technologies Inc. Successfully Completes Non-GLP Toxicity Analysis for Brain Cancer Sep 28 Theralase Technologies Inc. announced that it has received CAD 0.46 million in funding Sep 08
Second quarter 2023 earnings released Aug 30 Theralase Technologies Inc. announced that it has received CAD 1.2 million in funding Jul 01
High number of new directors Jun 14
Theralase Technologies Inc. Announces Appointment of Kaouthar Lbiati as Independent Director Jun 07
First quarter 2023 earnings released: CA$0.007 loss per share (vs CA$0.008 loss in 1Q 2022) Jun 02
Theralase Technologies Inc. Announces Chief Executive Officer Changes May 25
Theralase® Provides Update on Phase II Bladder Cancer Study May 12
No longer forecast to breakeven Apr 28
No longer forecast to breakeven Apr 27
Theralase® Phase II NMIBC Clinical Study (Interim) Data to be Presented at the ASCO GU Cancer Symposium Jan 26
Third quarter 2022 earnings released: CA$0.007 loss per share (vs CA$0.005 loss in 3Q 2021) Dec 01 Theralase Technologies Inc. announced that it has received CAD 0.25 million in funding Nov 18
Insufficient new directors Nov 16 Theralase Technologies Inc. announced that it has received CAD 2.5 million in funding Sep 23
Second quarter 2022 earnings released: CA$0.006 loss per share (vs CA$0.006 loss in 2Q 2021) Aug 31
Insufficient new directors Aug 01
Insufficient new directors Jul 02
First quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.004 loss in 1Q 2021) Jun 01
Full year 2021 earnings released: CA$0.022 loss per share (vs CA$0.027 loss in FY 2020) May 01
Theralase®Technologies Inc. Provides Update on Phase Ii Bladder Cancer Clinical Study Apr 06
Theralase® Demonstrates Proof-Of-Concept for Canadian-Made Covid-19 Vaccine Feb 08
Third quarter 2021 earnings: EPS in line with expectations, revenues disappoint Nov 30
Interim CEO & COO John Trikola has left the company Nov 28
Interim CEO & COO John Trikola has left the company Nov 28
Interim CEO & COO John Trikola has left the company Nov 28
Interim CEO & COO John Trikola has left the company Nov 28
Interim CEO & COO John Trikola has left the company Nov 28
Interim CEO & COO John Trikola has left the company Nov 28
Interim CEO & COO John Trikola has left the company Nov 28 Shareholder Returns TTX DE Medical Equipment DE Market 7D -4.1% 2.0% -0.02% 1Y 39.8% -2.7% 15.1%
See full shareholder returns
Return vs Market: TTX exceeded the German Market which returned 15.3% over the past year.
Price Volatility Is TTX's price volatile compared to industry and market? TTX volatility TTX Average Weekly Movement 19.4% Medical Equipment Industry Average Movement 6.4% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: TTX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: TTX's weekly volatility has decreased from 27% to 19% over the past year, but is still higher than 75% of German stocks.
About the Company Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ.
Show more Theralase Technologies Inc. Fundamentals Summary How do Theralase Technologies's earnings and revenue compare to its market cap? TTX fundamental statistics Market cap €43.68m Earnings (TTM ) -€2.93m Revenue (TTM ) €668.88k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TTX income statement (TTM ) Revenue CA$986.60k Cost of Revenue CA$476.43k Gross Profit CA$510.17k Other Expenses CA$4.84m Earnings -CA$4.33m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.017 Gross Margin 51.71% Net Profit Margin -438.78% Debt/Equity Ratio 0%
How did TTX perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 05:34 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Theralase Technologies Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Douglas Loe Echelon Wealth Partners Inc. Andre Uddin Research Capital Corporation
